{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glial+Tumor+of+Brain&page=5", "query": { "condition": "Glial Tumor of Brain", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 1044, "total_pages": 105, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glial+Tumor+of+Brain&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glial+Tumor+of+Brain&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T11:03:54.036Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00075491", "title": "Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "fenretinide", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2003-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-10-08T11:03:54.036Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075491" }, { "nct_id": "NCT01182350", "title": "Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Karen D. Wright MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 53, "start_date": "2011-09", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-10-08T11:03:54.036Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01182350" }, { "nct_id": "NCT03175224", "title": "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "Advanced Cancer", "Renal Cancer", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "NSCLC", "Lung Cancer", "Brain Tumor", "Glioblastoma Multiforme", "EGFR Gene Mutation", "MET Amplification", "HGF", "Thyroid Cancer", "Pancreatic Cancer", "Colon Cancer", "MET Alteration", "MET Fusion", "Exon 14 Skipping" ], "interventions": [ { "name": "APL-101 Oral Capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apollomics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 497, "start_date": "2017-09-27", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-10-08T11:03:54.036Z", "location_count": 6, "location_summary": "Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03175224" }, { "nct_id": "NCT00393094", "title": "Bevacizumab and Irinotecan to Treat Brain Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High-Grade Gliomas" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2006-09", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2012-07-13", "last_synced_at": "2026-10-08T11:03:54.036Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00393094" }, { "nct_id": "NCT00098761", "title": "VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "laromustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 42, "start_date": "2005-02", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2011-06-30", "last_synced_at": "2026-10-08T11:03:54.036Z", "location_count": 10, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098761" }, { "nct_id": "NCT05902169", "title": "Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma", "Recurrent Glioblastoma", "GBM" ], "interventions": [ { "name": "SonoCloud-9 (SC9)", "type": "DEVICE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "CarThera", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 560, "start_date": "2024-01-29", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-08T11:03:54.036Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05902169" }, { "nct_id": "NCT01116661", "title": "Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma" ], "interventions": [ { "name": "5-Aminolevuline Acid (ALA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 199, "start_date": "2010-08", "completion_date": "2019-02-28", "has_results": true, "last_update_posted_date": "2019-05-29", "last_synced_at": "2026-10-08T11:03:54.036Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01116661" }, { "nct_id": "NCT02323880", "title": "Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Central Nervous System Neoplasm", "Recurrent Childhood Glioblastoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Central Nervous System Neoplasm", "WHO Grade 3 Glioma" ], "interventions": [ { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 59, "start_date": "2015-10-30", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-10-08T11:03:54.036Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02323880" }, { "nct_id": "NCT07438860", "title": "Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Brain Tumors", "Glioma" ], "interventions": [ { "name": "SBK2-ICG", "type": "DRUG" }, { "name": "Craniotomy (Standard of Care)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Tiffany Hodges", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2026-11-02", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-08T11:03:54.036Z", "location_count": 2, "location_summary": "Cleveland, Ohio • Dayton, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Dayton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07438860" }, { "nct_id": "NCT04776980", "title": "Multimodality MRI and Liquid Biopsy in GBM", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Brain Tumor, Adult: Glioblastoma", "Brain Tumor, Recurrent", "Brain Tumor, Primary" ], "interventions": [ { "name": "Post Feraheme Infusion MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-06", "completion_date": "2022-06-22", "has_results": false, "last_update_posted_date": "2022-09-16", "last_synced_at": "2026-10-08T11:03:54.036Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04776980" } ] }